CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates - BioSpace

... intellectual property estate. Backed by €438 million in cash, we are ... FDA IND submission scheduled for H2 2025 and start of Phase 1 trial planned for ...